| 1345 |
National Cancer Institute |
Html |
en |
Where To Get Help When You Decide To Quit Smoking |
This fact sheet provides information about helpful resources for people who have decided to quit smoking. |
| pregnant smokers | 0.551074 |
| Monday | 0.355736 |
| health care provider | 0.663743 |
| Human Services | 0.458787 |
| smoking quitline | 0.772173 |
| past failures | 0.456683 |
| Control Research Branch | 0.617264 |
| online instant | 0.460766 |
| good sources | 0.488807 |
| fact sheet | 0.479049 |
| Disease Control | 0.471166 |
| Friday | 0.356769 |
| Spanish | 0.352479 |
| cessation counselors | 0.66457 |
| Handle Withdrawal Symptoms | 0.626098 |
| tobacco users | 0.460764 |
| local resources | 0.610693 |
| health care professionals | 0.901235 |
| Smokefree.gov Web site | 0.887035 |
| local cessation programs | 0.636749 |
| National Institutes | 0.468631 |
| a.m. | 0.357414 |
| toll-free number routes | 0.602386 |
| toll-free telephone quitline | 0.609664 |
| smoking-related questions | 0.477461 |
|
| NCI | 0.448064 |
| nicotine replacement products | 0.63931 |
| free materials | 0.471513 |
| Forever Free | 0.465092 |
| LiveHelp | 0.389817 |
| state-run quitlines | 0.469544 |
| support | 0.389277 |
| wide range | 0.469675 |
| resource information | 0.468257 |
| United States | 0.462426 |
| smokers | 0.602948 |
| specific action | 0.452212 |
| Express things | 0.451457 |
| smoking | 0.882754 |
| national resources | 0.480672 |
| free cessation assistance | 0.632049 |
| Eastern time | 0.627286 |
| smoking materials | 0.639653 |
| potential side effects | 0.490412 |
| Clear Horizons | 0.464946 |
| English | 0.352498 |
| science-driven tools | 0.47693 |
| one-on-one help | 0.476837 |
| information | 0.470963 |
|
CLICK HERE |
| 1401 |
National Cancer Institute |
Html |
en |
Depression (PDQ®)–Patient Version |
Expert-reviewed information summary about the diagnosis, assessment, and treatment of depression in adults and children who have cancer. |
| cancer treatment | 0.651741 |
| talk therapy | 0.584553 |
| cancer reacts | 0.573578 |
| PDQ cancer information | 0.709592 |
| specific symptoms | 0.575944 |
| children | 0.567594 |
| clinical trials | 0.590596 |
| major depression | 0.717529 |
| cancer information summary | 0.661683 |
| social support | 0.596519 |
| family members | 0.586314 |
| clinical trial | 0.577701 |
| breast cancer prevention | 0.582269 |
| risk factors | 0.576392 |
| cancer patients | 0.640384 |
| suicide | 0.586542 |
| cancer diagnosis | 0.641499 |
| daily life | 0.565808 |
| usual activities | 0.591649 |
| nerve cells | 0.617277 |
| symptoms | 0.713409 |
| NCI PDQ cancer | 0.615822 |
| anxiety | 0.567307 |
| effects | 0.576095 |
|
| treatment | 0.684675 |
| medicines | 0.607072 |
| Cancer Information Service | 0.595317 |
| personal history | 0.608756 |
| pancreatic cancer | 0.571142 |
| treatment clinical trials | 0.568602 |
| National Cancer Institute | 0.658955 |
| health care | 0.575207 |
| Palliative Care Editorial | 0.599921 |
| tricyclic antidepressants | 0.564862 |
| cancer pain | 0.568074 |
| new treatment | 0.572603 |
| Cancer Care page | 0.585295 |
| Care Editorial Board | 0.601242 |
| antidepressants | 0.660082 |
| active cancer treatment | 0.606386 |
| PDQ summary | 0.608172 |
| doctor | 0.608478 |
| cancer-related depression | 0.600613 |
| cancer information summaries | 0.594088 |
| comprehensive cancer information | 0.593479 |
| cancer | 0.885163 |
| depression | 0.980341 |
| reuptake inhibitors | 0.578298 |
|
CLICK HERE |
| 1440 |
National Cancer Institute |
Html |
en |
Genetics of Colorectal Cancer (PDQ®)–Health Professional Version |
Hereditary colorectal cancer syndromes include Lynch syndrome and several polyposis syndromes (familial adenomatous polyposis, MUTYH-associated polyposis, juvenile polyposis syndrome, Peutz-Jeghers syndrome, and serrated polyposis syndrome). Learn about the genetics, clinical manifestations, management, and psychosocial aspects of these and other hereditary colon cancer syndromes in this expert-reviewed summary. |
| hyperplastic polyps | 0.725031 |
| nondysplastic serrated polyps | 0.656585 |
| adenomatous polyps | 0.691874 |
| classic FAP burden | 0.649593 |
| colonic polyps | 0.652581 |
| colorectal cancer risk | 0.652487 |
| FAP patients | 0.932715 |
| colorectal cancer screening | 0.641111 |
| familial CRC risk | 0.634448 |
| duodenal adenomas | 0.717785 |
| polyps | 0.898156 |
| colorectal cancer | 0.915758 |
| large serrated polyps | 0.681431 |
| conventional hyperplastic polyps | 0.657048 |
| rectal cancer risk | 0.636363 |
| hereditary nonpolyposis colorectal | 0.723285 |
| CRC | 0.676743 |
| colorectal adenomatous polyps | 0.677785 |
| APC pathogenic variant | 0.710503 |
| familial adenomatous polyposis | 0.637625 |
| et al. | 0.674027 |
| adenomas | 0.856618 |
| study | 0.666989 |
| nonpolyposis colorectal cancer | 0.748743 |
| duodenal polyps | 0.793499 |
|
| polyp burden | 0.773382 |
| FAP family member | 0.659403 |
| hereditary colon cancer | 0.646397 |
| unselected CRC patients | 0.633325 |
| CpG island methylator | 0.649466 |
| Lynch syndrome patients | 0.681837 |
| pathogenic variants | 0.757278 |
| Advanced colorectal polyps | 0.671186 |
| serrated adenomas | 0.645858 |
| FAP families | 0.629309 |
| large adenomas | 0.639406 |
| Lynch syndrome | 0.829151 |
| FAP polyp burden | 0.677536 |
| colon cancer | 0.807611 |
| Abstract | 0.653383 |
| uncontrolled rectal polyps | 0.639399 |
| island methylator phenotype | 0.649038 |
| duodenal polyp burden | 0.68665 |
| FAP patients. | 0.679148 |
| SPS polyps | 0.632287 |
| family history | 0.768195 |
| cancer risk | 0.699194 |
| rectal cancer patients | 0.661401 |
| classic FAP | 0.64982 |
|
CLICK HERE |
| 1523 |
National Cancer Institute |
Html |
en |
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer. |
| Peritoneal Cancer Prevention | 0.227525 |
| treatment | 0.390762 |
| cancer treatment | 0.235396 |
| Peritoneal Cancer Treatment | 0.215309 |
| cancer cells | 0.337677 |
| body | 0.222684 |
| PDQ cancer information | 0.234419 |
| ovarian epithelial cancer | 0.590068 |
| fallopian tube cancers | 0.219247 |
| fallopian tube | 0.872006 |
| advanced ovarian epithelial | 0.202336 |
| fallopian tube cancer | 0.492956 |
| National Cancer Institute | 0.246576 |
| primary peritoneal cancer | 0.750448 |
| clinical trials | 0.486834 |
|
| cancer information summary | 0.212408 |
| clinical trial | 0.300455 |
| new treatment | 0.206874 |
| PDQ Ovarian Epithelial | 0.215884 |
| ovarian cancer | 0.427345 |
| patients | 0.208263 |
| primary peritoneal cancers | 0.298007 |
| peritoneal cancer form | 0.23692 |
| Recurrent ovarian epithelial | 0.234027 |
| Hereditary ovarian cancer | 0.23385 |
| cancer clinical trials | 0.21629 |
| stage | 0.222725 |
| fallopian tubes | 0.310827 |
| cancer | 0.950591 |
| information | 0.260881 |
|
CLICK HERE |
| 1578 |
National Cancer Institute |
Html |
en |
Salivary Gland Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of salivary gland cancer. |
| treatment | 0.350503 |
| cancer cells | 0.273747 |
| salivary gland tumors | 0.252711 |
| body | 0.202362 |
| Recurrent salivary gland | 0.246617 |
| PDQ cancer information | 0.209396 |
| clinical trial search | 0.221183 |
| National Cancer Institute | 0.225088 |
| clinical trials | 0.502843 |
| clinical trial | 0.428553 |
| fast neutron radiation | 0.275402 |
| patients | 0.211575 |
|
| salivary glands | 0.27815 |
| small salivary gland | 0.219313 |
| major salivary gland | 0.219682 |
| salivary gland cancer | 0.977675 |
| cancer clinical trials | 0.23079 |
| lymph node | 0.201663 |
| radiation therapy | 0.594263 |
| salivary gland cancers | 0.255838 |
| information | 0.215378 |
| diagnose salivary gland | 0.246491 |
| Minor salivary gland | 0.204078 |
| neutron radiation therapy | 0.270686 |
|
CLICK HERE |
| 1594 |
National Cancer Institute |
Html |
en |
Gallbladder Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of gallbladder cancer. |
| Primary gallbladder cancer | 0.47032 |
| bile ducts | 0.484867 |
| tissue | 0.379314 |
| body | 0.404589 |
| Gallbladder Cancer Treatment | 0.453363 |
| PDQ cancer information | 0.441195 |
| clinical trial search | 0.374973 |
| bile duct | 0.37352 |
| Endoscopic stent placement | 0.366691 |
| nearby lymph nodes | 0.402642 |
| cancer information summary | 0.414802 |
| clinical trial | 0.522846 |
| breast cancer prevention | 0.364901 |
| liver | 0.416883 |
| gallbladder surgery | 0.402266 |
| gallbladder stores | 0.412552 |
| patients | 0.384079 |
| blood vessels | 0.366084 |
| metastatic gallbladder cancer | 0.515618 |
| Unresectable cancer | 0.362347 |
| treatment clinical trial | 0.366014 |
| NCI PDQ cancer | 0.38278 |
| radiation therapy | 0.532352 |
| Treatment Editorial Board | 0.368907 |
|
| small intestine | 0.483884 |
| treatment | 0.503531 |
| gallbladder cancer | 0.938706 |
| transhepatic biliary drainage | 0.367562 |
| new cancer treatments | 0.372521 |
| NCI-supported cancer | 0.364603 |
| cancer cells | 0.513548 |
| Cancer Information Service | 0.372954 |
| common bile duct | 0.365877 |
| treatment clinical trials | 0.389845 |
| gallbladder cancer cells | 0.455848 |
| National Cancer Institute | 0.416909 |
| new treatment | 0.406145 |
| External radiation therapy | 0.364544 |
| stage gallbladder cancer | 0.491411 |
| ) layer. | 0.384877 |
| clinical trials | 0.742882 |
| Cancer Care page | 0.364553 |
| Blood. The cancer | 0.370595 |
| cancer research process | 0.366097 |
| cancer clinical trials | 0.40814 |
| tumor | 0.374261 |
| cancer information summaries | 0.371259 |
| comprehensive cancer information | 0.371502 |
|
CLICK HERE |
| 1810 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de páncreas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de páncreas. |
| resectable pancreatic | 0.421757 |
| Sin embargo | 0.468358 |
| largo plazo | 0.439685 |
| chemotherapy following curative | 0.48776 |
| Tumor Study Group | 0.478506 |
| curative resection | 0.550476 |
| fase iii | 0.665649 |
| Natl Cancer Inst | 0.419755 |
| after curative resection | 0.455925 |
| Arch Surg | 0.451242 |
| effective adjuvant combined | 0.42796 |
| gemcitabina versus | 0.464125 |
| quimiorradioterapia posoperatoria | 0.420132 |
| Gastrointestinal Intergroup | 0.4265 |
| Cameron JL | 0.507923 |
| periampullary region | 0.42716 |
| patients with | 0.44756 |
| randomized controlled | 0.421891 |
| Conlon KC | 0.442167 |
| Lillemoe KD | 0.42689 |
| EORTC gastrointestinal tract | 0.428698 |
| meses vs | 0.421884 |
| gastrointestinal tract | 0.431387 |
| following curative resection | 0.474649 |
| Yeo CJ | 0.5451 |
|
| M0 T2 | 0.428111 |
| M0 T1 | 0.424975 |
| chemotherapy after resection | 0.463442 |
| Regine WF | 0.420404 |
| M0 T3 | 0.428453 |
| pancreatic cancer | 0.97706 |
| as risk factors | 0.421112 |
| postoperative adjuvant chemoradiation | 0.455288 |
| versus gemcitabina | 0.456328 |
| Surg Oncol | 0.435512 |
| patients with resected | 0.42485 |
| Gastrointestinal Tumor Study | 0.48648 |
| páncreas estadio | 0.439198 |
| régimen off | 0.443587 |
| Grochow LB | 0.426604 |
| estadio iii | 0.623435 |
| Abrams RA | 0.46019 |
| Gy XRT | 0.450407 |
| Adjuvant chemotherapy with | 0.456373 |
| Stocken DD | 0.455773 |
| Oncology Group | 0.420611 |
| adjuvant combined | 0.442249 |
| quimioterapia posoperatoria | 0.432032 |
| 5-fluorouracil after curative | 0.42675 |
|
CLICK HERE |
| 1826 |
National Cancer Institute |
Html |
es |
Tratamiento del retinoblastoma (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del retinoblastoma en niños. |
| Fam Cancer | 0.224979 |
| second primary | 0.226983 |
| Moll AC | 0.230701 |
| bilateral retinoblastoma | 0.377316 |
| bilateral retinoblastoma treated | 0.303483 |
| Sin embargo | 0.262098 |
| cancers after radiotherapy | 0.220083 |
| with retinoblastoma | 0.99058 |
| retinoblastoma patients | 0.504149 |
| international classification | 0.229832 |
| hereditary retinoblastoma | 0.609301 |
| Imhof SM | 0.218892 |
| tumors among survivors | 0.21889 |
| with carboplatin | 0.219119 |
| retinoblastoma treated with | 0.391051 |
| retinoblastoma —una tasa | 0.309551 |
| gen rb1 | 0.264654 |
| Estados Unidos | 0.240611 |
| Natl Cancer Inst | 0.380536 |
| patients with | 0.285893 |
| second malignant neoplasms | 0.222801 |
| ectopic intracranial retinoblastoma | 0.30877 |
| survivors treated with | 0.222819 |
| retinoblastoma survivors | 0.803446 |
| Retinoblastoma Families | 0.301592 |
|
| heritable retinoblastoma survivors | 0.400266 |
| long-term survivors | 0.281356 |
| orientación genética | 0.258139 |
| Abramson DH | 0.390414 |
| with retinoblastoma treated | 0.311845 |
| rb1 mutations | 0.229834 |
| sporadic unilateral retinoblastoma | 0.309266 |
| Retinoblastoma Survivor Study | 0.395385 |
| Second nonocular tumors | 0.222288 |
| Pediatr Blood Cancer | 0.370166 |
| retinoblastoma treated | 0.437026 |
| novel retinoblastoma | 0.302896 |
| Arch Ophthalmol | 0.218403 |
| International Retinoblastoma Staging | 0.430669 |
| sección retinoblastoma | 0.316419 |
| Clin Oncol | 0.275713 |
| sistema nervioso central | 0.230398 |
| tumor progresa | 0.220651 |
| Retinoblastoma Staging System | 0.431448 |
| among long-term survivors | 0.238413 |
| Shields CL | 0.248375 |
| retinoblastoma tumours | 0.300442 |
| Marees T | 0.232711 |
| retinoblastoma patients reveals | 0.307846 |
|
CLICK HERE |
| 3423 |
National Cancer Institute |
Html |
es |
Tintes para el cabello y el riesgo de cáncer |
Hoja informativa que analiza las investigaciones sobre la posible conexión entre los tintes para el cabello de uso personal y el cáncer. |
| Garcia-Closas M | 0.306371 |
| Harling M | 0.306346 |
| La Vecchia C | 0.308404 |
| American Medical Association | 0.308091 |
| Personal permanent | 0.308814 |
| Costantini AS | 0.305724 |
| pequeño aumento | 0.306764 |
| lymphoid neoplasms | 0.305705 |
| case-control study | 0.330749 |
| sustancias quÃmicas llamadas | 0.319289 |
| linfoma no-Hodgkin | 0.315605 |
| IARC Monographs | 0.307567 |
| New England bladder | 0.317677 |
| dye products | 0.311357 |
| Benvenuti A | 0.306313 |
| Occupational Health | 0.305772 |
| Sanjose S | 0.317218 |
| Estados Unidos | 0.315003 |
| resultados contradictorios | 0.358008 |
| hematolymphopoietic malignancies | 0.305757 |
| PubMed Abstract | 0.927635 |
| on carcinogenicity | 0.306299 |
| International Agency | 0.31736 |
| International Journal | 0.345823 |
| análisis conjunto | 0.313039 |
|
| Nieters A | 0.306464 |
| Bolt HM | 0.305479 |
| Critical Reviews | 0.305548 |
| Nienhaus A | 0.305624 |
| leucemia aguda | 0.319649 |
| non-Hodgkin lymphoma | 0.305903 |
| is not | 0.31478 |
| Carcinogenic Risks | 0.30569 |
| aminas aromáticas | 0.321464 |
| Dulon M | 0.30623 |
| Epidemiology Biomarkers | 0.309054 |
| Thun MJ | 0.305441 |
| Etminan M | 0.306466 |
| Hamann CR | 0.305758 |
| determinados tipos | 0.306529 |
| Kogevinas M | 0.306372 |
| Aben KK | 0.305435 |
| Gago-Dominguez M | 0.314868 |
| Sandler DP | 0.305457 |
| case-control study from | 0.31306 |
| Some Aromatic Amines | 0.30908 |
| Schablon A | 0.305625 |
| Montes-Martinez A | 0.305837 |
| Decarli A | 0.305736 |
|
CLICK HERE |
| 3567 |
National Cancer Institute |
Html |
en |
NCI-Designated Cancer Centers |
NCI-designated cancer centers are at the forefront of NCI-supported cancer research efforts at universities and cancer research centers across the United States. |
| Basic Laboratory Cancer | 0.40308 |
| cancer prevention | 0.219474 |
| United States | 0.258952 |
| promising laboratory discoveries | 0.246618 |
| successful investigator-initiated grants | 0.242213 |
| NCI grant funding | 0.273266 |
| cancer center investigators | 0.372566 |
| Cancer Centers conduct | 0.328404 |
| university medical centers | 0.293855 |
| research capabilities | 0.206064 |
| individual cancer center | 0.29193 |
| fosters cancer programs | 0.290926 |
| NCI Cancer Centers | 0.39489 |
| cutting-edge cancer treatments | 0.306989 |
|
| cancer research effort | 0.342261 |
| Comprehensive Cancer Centers | 0.42681 |
| NCI-Designated Cancer Center | 0.361383 |
| new treatments | 0.264162 |
| cancer patients | 0.223724 |
| cancer diagnosis | 0.215839 |
| basic laboratory research | 0.296921 |
| cancer centers | 0.970403 |
| substantial transdisciplinary research | 0.27523 |
| cancer clinical trials | 0.286407 |
| Laboratory Cancer Centers | 0.418647 |
| cancer survivors | 0.215279 |
| research studies | 0.213208 |
|
CLICK HERE |